MIRA Pharmaceuticals Advances in Clinical Trials and SKNY Acquisition

MIRA Pharmaceuticals, a company specializing in therapeutics for neurologic disorders, announced its participation in the BIO International Convention 2025 in Boston. Key focus areas include licensing and strategic alliances as well as mergers and acquisitions opportunities.

Ketamir-2, MIRA's leading candidate, is currently advancing through Phase 1 clinical trials, with plans to enter Phase IIa targeting neuropathic pain. This potential non-opioid solution aims to address chronic pain management needs.

MIRA is also preparing regulatory documentation for its acquisition of SKNY Pharmaceuticals. SKNY-1, a promising candidate targeting smoking cessation and obesity, acts on CB1, CB2, and MAO-B receptors.

CEO Erez Aminov emphasizes the company's momentum across its pipeline, focusing on strategic growth through partnerships. Dr. Angel, Chief Scientific Advisor, highlights Ketamir-2's potential as a new class of non-opioid therapies.